Baxter International Management

Management criteria checks 3/4

Baxter International's CEO is Joe Almeida, appointed in Jan 2016, has a tenure of 6.83 years. total yearly compensation is $15.63M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.063% of the company’s shares, worth €16.66M. The average tenure of the management team and the board of directors is 4.6 years and 5.8 years respectively.

Key information

Joe Almeida

Chief executive officer

US$15.6m

Total compensation

CEO salary percentage	8.3%
CEO tenure	6.8yrs
CEO ownership	0.06%
Management average tenure	4.6yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joe Almeida's remuneration changed compared to Baxter International's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	US$16m	US$1m	US$1b
Sep 30 2021	n/a	n/a	US$1b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$16m	US$1m	US$1b
Sep 30 2020	n/a	n/a	US$911m
Jun 30 2020	n/a	n/a	US$924m
Mar 31 2020	n/a	n/a	US$991m
Dec 31 2019	US$14m	US$1m	US$1b
Sep 30 2019	n/a	n/a	US$1b
Jun 30 2019	n/a	n/a	US$1b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$16m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$795m
Mar 31 2018	n/a	n/a	US$840m
Dec 31 2017	US$15m	US$1m	US$609m
Sep 30 2017	n/a	n/a	US$1b
Jun 30 2017	n/a	n/a	US$904m
Mar 31 2017	n/a	n/a	US$2b
Dec 31 2016	US$6m	US$1m	US$5b
Sep 30 2016	n/a	n/a	US$5b
Jun 30 2016	n/a	n/a	US$5b
Mar 31 2016	n/a	n/a	US$4b
Dec 31 2015	US$8m	US$232k	US$393m

Compensation vs Market: Joe's total compensation ($USD15.63M) is above average for companies of similar size in the German market ($USD4.53M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

CEO

Joe Almeida (60 yo)

6.8yrs

Tenure

US$15,634,734

Compensation

Mr. Jose E. Almeida, also known as Joe, has been the Chairman of the Board and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President since January 01, 2016....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jose Almeida	Chairman of the Board	6.8yrs	US$15.63m	0.063% $ 16.7m
James Saccaro	Executive VP & CFO	7.4yrs	US$4.46m	0.028% $ 7.3m
Giuseppe Accogli	Executive VP & COO	less than a year	US$5.84m	0.015% $ 4.0m
Andrew Frye	President of Patient Support Systems	no data	US$4.71m	0.0024% $ 635.5k
Cristiano Franzi	Senior VP & President for EMEA	5.2yrs	US$4.41m	0.011% $ 2.9m
Brian Stevens	Senior VP	4yrs	no data	0.0020% $ 532.7k
Talvis Love	Senior VP & Chief Information Officer	2.1yrs	no data	no data
Clare Trachtman	Vice President of Investor Relations	no data	no data	no data
David Rosenbloom	Senior VP & General Counsel	less than a year	no data	no data
Stacey Eisen	Senior Vice President of Global Communications	no data	no data	no data
Jeanne Mason	Senior Vice President of Human Resources	5.5yrs	US$4.14m	0.025% $ 6.6m
Jacqueline Kunzler	?Senior VP & Chief Quality Officer	no data	no data	0.0030% $ 783.2k

4.6yrs

Average Tenure

56yo

Average Age

Experienced Management: BTL's management team is considered experienced (4.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jose Almeida	Chairman of the Board	6.8yrs	US$15.63m	0.063% $ 16.7m
Robert Parkinson	Chairman Emeritus	6.8yrs	US$17.88m	no data
Thomas Chen	Independent Director	10yrs	US$336.96k	0.0049% $ 1.3m
Albert P. Stroucken	Lead Independent Director	18.2yrs	US$373.24k	0.0074% $ 2.0m
Peter Wilver	Director	less than a year	no data	0.00049% $ 129.2k
Stephen Oesterle	Independent Director	5.8yrs	US$352.49k	0.0032% $ 857.0k
Patricia Morrison	Independent Director	3.8yrs	US$322.99k	0.0020% $ 532.7k
Nancy Schlichting	Independent Director	less than a year	US$70.15k	0.00068% $ 179.3k
Catherine Smith	Independent Director	5.8yrs	US$336.99k	0.0022% $ 590.7k
David Wilkes	Independent Director	1.8yrs	US$346.81k	0.0011% $ 279.5k
Michael Mahoney	Independent Director	7.1yrs	US$335.23k	0.0050% $ 1.3m
Amy Wendell	Independent Director	3.8yrs	US$331.23k	no data

5.8yrs

Average Tenure

64yo

Average Age

Experienced Board: BTL's board of directors are considered experienced (5.8 years average tenure).

Baxter International Management

Management criteria checks 3/4

Key information

Recent management updates

Baxter International Inc., Annual General Meeting, May 07, 2024

Baxter International Inc. Announces Management Appointments

Baxter International Inc. Announces Board Changes

Baxter International Inc. Appoints William Ampofo to Its Board of Directors

Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023

Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses

Recent updates

Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Baxter International Inc., Annual General Meeting, May 07, 2024

Baxter International Inc. Declares Quarterly Dividend, Payable on April 1, 2024

Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024

Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023

Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

Baxter International Inc. Announces Management Appointments

Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Baxter International Inc. Announces Board Changes

The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws

Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023

Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc

Baxter International Inc. Appoints William Ampofo to Its Board of Directors

Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth Index

Baxter International Inc. Announces James K. Saccaro Notifies to Resign as Executive Vice President, Effective as of May 31, 2023

Advent International Corporation and Warburg Pincus LLC signed a definitive agreement to acquire Baxter Pharmaceutical Solutions LLC from Baxter International Inc. (NYSE:BAX) for $4.3 billion.

Baxter International Inc. Selects Chris Toth to Be Chief Executive Officer of the Company’s Planned Spinoff of Its Renal Care and Acute Therapies Businesses

Baxter International Inc. Announces Management Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on April 3, 2023

Baxter International Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2022

Baxter International Inc. Announces Resignation of Giuseppe Accogli as Executive Vice President and Chief Operating Officer

Baxter Introduces ExactaMix Pro Automated Compounder

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on January 3, 2023

Baxter International Inc. Highlights New Home Dialysis and HDX Therapy Data in 14 Clinical Presentations At Kidney Week 2022

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Baxter International Inc. to Report Q3, 2022 Results on Oct 27, 2022

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

Upcoming dividend of US$0.29 per share

Second quarter 2022 earnings released: EPS: US$0.25 (vs US$0.59 in 2Q 2021)

Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2022

Baxter International Inc. Announces Executive Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on October 3, 2022

Upcoming dividend of US$0.29 per share

Baxter International Inc. Announces Board Changes

Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2022

First quarter 2022 earnings released: EPS: US$0.14 (vs US$0.59 in 1Q 2021)

Baxter International Inc. Announces Findings of an Observational Study on Data from the Starling Registry

Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital

Baxter International Inc., Annual General Meeting, May 03, 2022

Baxter International Inc. Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Baxter International Inc. Provides Earnings Guidance for the First Quarter and Year of 2022

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on April 1, 2022

Baxter International Inc. (NYSE:BAX) completed the acquisition of Hill-Rom Holdings, Inc. (NYSE:HRC).

Upcoming dividend of US$0.28 per share

Third quarter 2021 earnings released: EPS US$0.90 (vs US$0.70 in 3Q 2020)

Baxter International Inc. Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation

Baxter Reportedly in Advanced Talks to Acquire Hill-Rom for About $10 Billion

Upcoming dividend of US$0.28 per share

Second quarter 2021 earnings released: EPS US$0.59 (vs US$0.48 in 2Q 2020)

Baxter International Inc.(NYSE:BAX) dropped from Russell 1000 Growth-Defensive Index

Baxter International Inc. Presents Data At 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations

Baxter Launches the Sharesource Analytics 1.0 Digital Health Module to Enhance Clinical Management of Home Dialysis Patients

Bernstein Litowitz Berger & Grossmann LLP and Kessler Topaz Meltzer & Check, LLP Announce Settlement of Class Action Involving Purchasers of Baxter International Inc. Common Stock

Upcoming dividend of US$0.28 per share

Baxter International Inc. Launches PrisMax2 System to Advance Critical Care Delivery for Patients and Hospitals

Independent Director has left the company

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on July 1, 2021

First quarter 2021 earnings released: EPS US$0.59 (vs US$0.66 in 1Q 2020)

Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2021

Baxter Announces U.S. FDA 510(K) Clearance of AK 98 Hemodialysis Machine

Baxter International Inc. Announces Board Changes

Baxter International Inc. Announces Board Changes

Full year 2020 earnings released: EPS US$2.17 (vs US$1.97 in FY 2019)